Innate Pharma S.A. ADS (IPHA)
Stock · NASDAQ · Health Care
$2.22as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$1.76
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 164
- Website
- www.innate-pharma.com
Fundamentals
- 1-day range
- $1.72$1.73
- Market cap
- $167.42M
- P/E (trailing)
- —
- P/E (forward)
- -2.73
- EPS (trailing)
- $-0.64
- Dividend yield
- —
- Beta
- 0.86
- Avg. volume
- 64.1K
52-week range
$1.17$2.62
Next earnings: September 17, 2026 · EPS estimate $-0.08
Forecasts
4 analyst ratings
Buy 75%
Hold 25%
Sell 0%
1-year price forecast
High
$8
+260.4%
Median
$6.5
+192.8%
Low
$3
+35.1%
Innate Pharma S.A. ADS Competitors
Chosen by industry and closest market cap.
- IPHAInnate Pharma S.A. ADS$2.22▼ 0.45%Market cap $167.42MP/E —$1.17$2.62
- ABOSAcumen Pharmaceuticals Inc. Common Stock$2.92▼ 3.63%Market cap $164.68MP/E —$1.21$3.6
- LENZLENZ Therapeutics Inc. Common Stock$5.12▲ 6.34%Market cap $163.67MP/E —$4.54$50.4
- MOLNMolecular Partners AG American Depositary Shares$4.5▼ 3.27%Market cap $163.47MP/E —$2.66$3.96
- CRBUCaribou Biosciences Inc. Common Stock$1.62▼ 2.41%Market cap $162.66MP/E —$1.38$3.54
- ARMPArmata Pharmaceuticals Inc. Common Stock$5.24▼ 3.50%Market cap $172.54MP/E —$2.4$16.34
- HUMAHumacyte Inc. Common Stock$0.6538▼ 5.66%Market cap $157.54MP/E —$0.5261$2.55
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IPHA Innate Pharma S.A. ADS | $167.42M | — | $2.22 | ▼ 0.45% | $1.17$2.62 |
| ABOS Acumen Pharmaceuticals Inc. Common Stock | $164.68M | — | $2.92 | ▼ 3.63% | $1.21$3.6 |
| LENZ LENZ Therapeutics Inc. Common Stock | $163.67M | — | $5.12 | ▲ 6.34% | $4.54$50.4 |
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $4.5 | ▼ 3.27% | $2.66$3.96 |
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $1.62 | ▼ 2.41% | $1.38$3.54 |
| ARMP Armata Pharmaceuticals Inc. Common Stock | $172.54M | — | $5.24 | ▼ 3.50% | $2.4$16.34 |
| HUMA Humacyte Inc. Common Stock | $157.54M | — | $0.6538 | ▼ 5.66% | $0.5261$2.55 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 184.0K
- Total value held
- $235.5K
- Institutional holders
- 9
Top holders this quarter
- Unknown81.2K
- Unknown43.5K
- Unknown43.4K
- Unknown10.1K
- Unknown4.7K
- Unknown861
- Unknown240
- Unknown10
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.